Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 791-797

  Oki, Yasunari ^a   Hirose, Takashi ^a   Yamaoka, Toshimitsu ^a   Kusumoto, Sojiro ^a   Shirai, Takao ^a   Sugiyama, Tomohide ^a   Okuda, Kentaro ^a   Nakashima, Masanao ^a   Murata, Yasunori ^a   Ohmori, Tohru ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Non small cell lung cancer; S 1; Second line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NEDAPLATIN; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXONIC ACID; SURVIVAL RATE; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 79954451023     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1382-1     Document Type: Article

References (33)

1. NSCLC Meta-Analyses Collaborative Group 2008 Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systemic review and meta-analysis of individual patient data from 16 randomized control trials J Clin Oncol 26 4617 4625 10.1200/JCO.2008.17.7162
2. FA Shepherd J Dancey R Ramlau, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 10811675 1:CAS:528:DC%2BD3cXktVyjsLc%3D (Pubitemid 30324363)
3. FA Shepherd JR Pereira T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
4. I Ringel SB Horwitz 1991 Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol J Natl Cancer Inst 83 288 291 1671606 10.1093/jnci/83.4.288 1:CAS:528:DyaK3MXisVSjtLY%3D
5. FV Fossella R Devore RN Kerr, et al. 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2354 2362 10856094 1:CAS:528:DC%2BD3cXkvFWrsLg%3D (Pubitemid 30415821)
6. T Shirasaka K Nakano T Takechi, et al. 1996 Antitumor activity of 1 M tegarur- 0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602 2606 8653704 1:CAS:528:DyaK28XjtlCgurg%3D (Pubitemid 26171684)
7. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009 7689420 1:CAS:528:DyaK3sXmtFKqsrk%3D (Pubitemid 23267702)
8. M Kawahara K Furuse Y Segawa, et al. 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 939 943 11592762 10.1054/bjoc.2001.2031 1:CAS:528:DC%2BD3MXot1SktLg%3D (Pubitemid 33015993)
9. BT Hill RDH Whelan SA Shellard, et al. 1994 Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro Invest New Drugs 12 169 182 7896535 10.1007/BF00873957 1:CAS:528:DyaK2MXjsVCmtb4%3D (Pubitemid 24376401)
10. Y Wada K Yoshida T Suzuki, et al. 2006 Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines Int J Cancer 119 783 791 16557585 10.1002/ijc.21879 1:CAS:528:DC%2BD28XntVeqtrY%3D (Pubitemid 44055889)
11. I Takahashi Y Emi Y Kakeji, et al. 2005 Increased antitumor activity in combined treatment TS-1 and docetaxel Oncology 68 130 137 16006750 10.1159/000086767 1:CAS:528:DC%2BD2MXntFSntLc%3D (Pubitemid 41158968)
12. A Suto T Kubota M Fukushima, et al. 2006 Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice Oncol Rep 15 1517 1522 16685389 1:CAS:528:DC%2BD28XlvVOis7k%3D
13. S Atagi M Kawahara Y Kusunoki, et al. 2008 Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer J Thorac Oncol 3 1012 1017 18758304 10.1097/JTO.0b013e318183f8ed
14. Yanagihara K, Yoshimura K, Niimi M et al (2010) Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol (Epub ahead of print)
15. K Yoshida M Ninomiya N Takakura, et al. 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407 16740764 10.1158/1078-0432.CCR-05-2425 1:CAS:528: DC%2BD28XltFyis7k%3D
16. K Yamaguchi T Shimamura I Hyodo, et al. 2006 Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer Br J Cancer 94 1803 1808 16773074 10.1038/sj.bjc.6603196 1:CAS:528:DC%2BD28XlsFequ7Y%3D (Pubitemid 43884569)
17. I Takahashi Y Emi Y Kakeji, et al. 2006 Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer Oncol Rep 15 849 854 16525670 1:CAS:528:DC%2BD28Xjs1Kitrw%3D
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines) J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
19. N Hanna FA Shepherd FV Fossela, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 15117980 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D (Pubitemid 41079796)
20. ES Kim V Hirsh T Mok, et al. 2008 Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial Lancet 372 1809 1818 19027483 10.1016/S0140-6736(08)61758-4 1:CAS:528:DC%2BD1cXhsVWhtbjM
21. CG Azzoli S Baker Jr S Temin, et al. 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 6251 6266 19917871 10.1200/JCO.2009.23.5622 1:CAS:528:DC%2BC3cXht1agsbs%3D
22. W Shuette S Nagel T Blankenburg, et al. 2005 Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel J Clin Oncol 23 8389 8395 10.1200/JCO.2005.02. 3739
23. S Vazquez C Grande M Amenedo, et al. 2004 Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00) Anti-Cancer Drugs 15 489 494 15166623 10.1097/01.cad.0000127333.06439.0e 1:CAS:528:DC%2BD2cXktlajsr8%3D (Pubitemid 38736947)
24. CJ Sweeney J Zhu AB Sandler, et al. 2001 Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 Cancer 92 2639 2647 11745199 10.1002/1097-0142(20011115)92:10<2639::AID- CNCR1617>3.0.CO;2-8 1:STN:280:DC%2BD3Mnps1aqtA%3D%3D (Pubitemid 33049448)
25. N Helbekkmo U Aasebo SH Sundstrom, et al. 2008 Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy Lung Cancer 62 253 260 18417246 10.1016/j.lungcan.2008. 03.003
26. D Pectasides M Pectasides D Farmakis, et al. 2005 Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial Ann Oncol 16 294 299 15668287 10.1093/annonc/mdi053 1:STN:280:DC%2BD2M%2FjvFyhtg%3D%3D (Pubitemid 40309313)
27. FM Wachters HJM Groen B Biesma, et al. 2005 A randomized phase II trial of docetaxel versus docetaxel and irinotecan in patients with stage IIIB-IV non-small-cell lung cancer who failed first-line treatment Br J Cancer 17 15 20 10.1038/sj.bjc.6602268 (Pubitemid 40188429)
28. K Takeda S Negoro T Tamura, et al. 2009 Phase III trail of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104) Ann Oncol 20 835 841 19164456 10.1093/annonc/mdn705 1:STN:280:DC%2BD1MzgvVyntg%3D%3D
29. GV Scaliotti P Parikh J von Pawel, et al. 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced stage non-small-cell lung cancer J Clin Oncol 26 3543 3551 10.1200/JCO.2007.15.0375
30. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Eng J Med 350 2129 2139 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
31. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
32. DY Zang DH Yang HW Lee, et al. 2009 Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age Cancer Chemother Pharmacol 63 509 516 18481067 10.1007/s00280-008-0768-9 1:CAS:528:DC%2BD1cXhsFejtrjM
33. GJ Weiss C Langer R Rosell, et al. 2006 Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 24 4405 4411 16983108 10.1200/JCO.2006.06.7835 1:CAS:528:DC%2BD28XhtVyisrrN (Pubitemid 46630978)